Close Menu

David Hamilton at VentureBeat has an article on XDx, a molecular diagnostic company focusing on gene expression tests, which just filed for an IPO to raise as much as $87 million. The article lays out the case for gene-expression-based diagnostics, but also notes that so far these tests have "been slow to catch on." The article runs through similar existing tests, and gives a nice snapshot of the XDx business.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.